|
WO2020169747A1
|
|
Use of materials made of cross-linked beta-cyclodextrins for the treatment of tuberculosis
|
|
WO2020169707A1
|
|
Foxo1 inhibitor for use in the treatment of latent virus infection
|
|
WO2020165379A1
|
|
Plga-based microspheres, preparation methods and uses thereof
|
|
WO2020165370A1
|
|
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
WO2020165315A1
|
|
Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml)
|
|
WO2020161267A1
|
|
Methods for preparing extracellular vesicles (ev) depletemedia
|
|
WO2020161122A1
|
|
Recombinant vectors suitable for the treatment of ipex syndrome
|
|
WO2020161083A1
|
|
Methods and compositions for modulating blood-brain barrier
|
|
WO2020157131A1
|
|
Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
|
|
WO2020157129A1
|
|
Optimisation of the scurfy model for in vivo testing of innovative treatments of autoimmunity
|
|
EP3712898A1
|
|
Method of predicting whether a kidney transplant recipient is at risk of having allograft loss
|
|
WO2020170001A1
|
|
Device and method for patient exercising in aquatic conditions
|
|
AU2018387826A1
|
|
Constructs comprising neuronal viability factors and uses thereof
|
|
EP3706728A1
|
|
S1pr2 antagonists for treating diseases involving abnormal immune responses
|
|
US2020256879A1
|
|
Methods and compositions for predicting and treating intracranial aneurysm
|
|
US2020268837A1
|
|
Methods and pharmaceutical compositions for modulating autophagy
|
|
WO2018011107A1
|
|
Use of er-alpha 46 in methods and kits for assessing the status of breast cancer
|
|
WO2018007555A1
|
|
Method for diagnosing cancer
|
|
WO2018011040A1
|
|
Plga microparticles loaded with a fluoroquinolone for the treatment of respiratory diseases
|
|
WO2018002147A1
|
|
Detection of borealin mutations for diagnosing thyroid dysgenesis
|
